Sponsors (32)
The bill greatly expands no‑cost HIV prevention access and funds outreach and training—reducing barriers and disparities—but does so at meaningful fiscal and administrative cost and raises privacy, implementation, and litigation risks that will need active management.
People across public and private programs (private employer and individual plans, Medicaid/CHIP, Medicare, VA/TRICARE, federal/tribal/IHS) will receive FDA‑approved HIV prevention drugs, related labs, and follow‑up with no cost‑sharing, cutting out‑of‑pocket costs and lowering barriers to prevention.
Uninsured and underinsured people will gain access to PrEP/PEP services, adherence support, and navigators through federally funded programs, improving uptake and retention among populations overrepresented in the domestic epidemic.
Clinicians and health professionals will receive training and culturally competent public outreach will be funded, increasing provider offering of PrEP/PEP and improving awareness in disproportionately affected communities.
Expanding no‑cost preventive coverage and funding outreach will increase federal and state spending and may require offsets or higher taxpayer costs.
Insurers and public programs will face higher drug and administrative costs that could be passed back to consumers through higher premiums or strain program sustainability if drug prices remain high.
New reporting, monitoring, and coverage changes will impose administrative and implementation burdens on insurers, state Medicaid/CHIP programs, providers, and plans (including 10‑year reporting), raising compliance costs and transitional work.
Based on analysis of 20 sections of legislative text.
Mandates private plans cover FDA‑approved HIV prevention drugs and related services without cost‑sharing or routine prior authorization; funds PrEP/PEP grants and education; strengthens confidentiality and enforcement.
Official title: To increase access to pre-exposure prophylaxis to reduce the transmission of HIV.
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
Requires private group and individual health plans to cover FDA‑approved HIV prevention drugs (PrEP and PEP) and related clinical services without cost‑sharing and generally without prior authorization, strengthens confidentiality for people seeking these services, prohibits discrimination by life/disability/long‑term care insurers based on use of HIV prevention medication, and creates new HHS obligations for enforcement, monitoring, public/provider education campaigns, and grant funding to expand access for uninsured and underinsured people. The bill also creates a private right of action and reporting requirements for plans and issuers, and authorizes appropriations for education and grant programs through FY2030.